An agent that clears disease-associated amyloid aggregates from the brains of patients with Alzheimer's disease does not alleviate disease progression. Yet this disappointing news should not rule out such potential therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hardy, J. & Selkoe, D. J. Science 297, 353–356 (2002).
Holmes, C. et al. Lancet 372, 216–223 (2008).
Schenk, D. et al. Nature 400, 173–177 (1999).
Brody, D. L. & Holtzman, D. M. Annu. Rev. Neurosci. 31, 175–193 (2008).
Bayer, A. J. et al. Neurology 64, 94–101 (2005).
Orgogozo, J.-M. et al. Neurology 61, 46–54 (2003).
Price, J. L. & Morris, J. C. Ann. Neurol. 45, 358–368 (1999).
Gómez-Isla, T. et al. J. Neurosci. 16, 4491–4500 (1996).
Lewis, J. et al. Science 293, 1487–1491 (2001).
Oddo, S. et al. Neuron 43, 321–332 (2004).
Fagan, A. M. et al. Ann. Neurol. 59, 512–519 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holtzman, D. Moving towards a vaccine. Nature 454, 419–420 (2008). https://doi.org/10.1038/454418a
Published:
Issue Date:
DOI: https://doi.org/10.1038/454418a
